Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exelixis and Sanofi Genzyme.

Optimizing Outcomes in Prostate Cancer: Matching Treatment to Patient in the Modern Era

Release Date: July 27, 2020
Expiration Date: July 27, 2021

Activity Overview

This online, on-demand virtual symposium brings together a renowned multidisciplinary group of experts in the management of prostate cancer who discuss significant advances in treatment, particularly for patients with castration-resistant prostate cancer (CRPC). New therapeutics allow physicians to target previously unattainable treatment goals for patients who might have received suboptimal therapy. Using challenging clinical case studies, the experts discuss how data on new treatments and treatment sequencing strategies can be used in scenarios of advanced and metastatic CRPC. Key topics include results from landmark clinical trials, new agents, and ongoing clinical trials.

This educational activity is an archive of a live virtual symposium held on July 14, 2020.

Acknowledgement of Support

This activity is supported by educational grants from Exelixis and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and urologists interested in the treatment of prostate cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with prostate cancer are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss key data from clinical trials regarding the evidence-based management of patients with prostate cancer utilizing currently available therapies.
  • Describe emerging strategies from ongoing late-phase clinical trials investigating novel therapies for prostate cancer.
  • Utilize evidence-based guidelines and clinical trial evidence to guide treatment selection and therapy sequencing along the prostate cancer disease continuum.
  • Implement personalized strategies to optimize treatment for patients with early-stage and advanced prostate cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Philip Kantoff, MD
Philip Kantoff, MD
Chairman of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical School
George J. Bosl Professor of Medicine
New York, NY

Disclosures: Consultant: Bavarian Nordic Immunotherapeutics, DRGT, GE Healthcare, Janssen, OncoCellMDX, Progenity, Seer Biosciences, Tarveda Therapeutics (previously Blend); Shareholder: Context Therapeutics LLC, DRGT, Placon, Seer Biosciences; Other: Member of Company Board and Investment Interest: Context Therapeutics LLC; Data Safety Monitoring Board: Merck and Genentech/Roche.

Celestia S. Higano, MD, FACP
Celestia S. Higano, MD, FACP
Professor, Medicine and Urology
University of Washington
Member, Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosures: Grant Research Support: Aragon, Astellas, AstraZeneca, Clovis, Dendreon, eFFECTOR Therapeutics, Emergent, Ferring, Genentech, Hoffman-Laroche, Medivation, Pfizer, Bayer, Memorial Sloan Kettering/Bayer; Other: Sponsored Speaker: Astellas; Advisory Board and Steering Committee: Bayer, Clovis, Ferring; Advisory Board and Telecon: Orion; Advisory Board: Blue Earth Diagnostics, Hinova, Janssen, Merck, Carrick Therapeutics, Novartis; Advisory Telecon: Tolmar; Grand Rounds: Genentech; Interview: Dendreon; Steering Committee: Pfizer.

Daniel P. Petrylak, MD
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Yale School of Medicine
Director, Prostate and Genitourinary Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant Research Support: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Astellas,AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics; Consultant: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, Urogen; Shareholder: Bellicum, Tyme (sold 10/2019).

Oliver Sartor, MD
Oliver Sartor, MD
C.E. & Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, LA

Disclosures: Grant Research Support: Advanced Accelerator Applications, AstraZeneca, Bayer, Constellation, Dendreon, Endocyte, Innocrin, Invitae, Janssen, Merck, Progenics, Sanofi, SOTIO; Consultant: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth, Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Janssen, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By